Milestones Payments. Roche Bioscience shall pay Tularik the following amounts within thirty (30) days after each occurrence of the following events. Each payment under this Section 9.4.1 shall be made for, and only for, the first Roche Bioscience Compound directed against each particular Target that achieves such milestone. Payment Milestone ------------------------------------------------------------------------------ [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] Roche Bioscience shall notify Tularik of the occurrence of each milestone for each Roche Bioscience Compound. Such milestone payments shall be non-refundable [ * ]. Further milestone payments shall not be paid with respect to any particular Roche Bioscience Compound if it [ * ]. If a Roche Bioscience Compound is developed for additional Roche Bioscience Indications, [ * ]. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Milestones Payments. 20 9.4.2 Additional Clinical Milestones........................... 21 9.4.3
Milestones Payments. Subject to the terms and conditions of this Agreement, Trevi will pay Penwest a milestone payment upon the first occurrence of each of the following events, no later than [**] after the occurrence of the event:
Milestones Payments. CPI shall make payments to SVI for development of a Royalty Product in accordance with the milestones identified generally below, and described with more particularity in the Project Plan (the “Milestones”). Notwithstanding Section 4(A), 4(B) and 4(C) below, a Milestone Payment is due and payable only if (x) the New Lead is a Royalty Product (i.e., covered by an issued Royalty Patent), and (y) the License Agreement is in full force and effect on the date such Milestone Payment would otherwise become due. If a New Lead that was not a Royalty Product at the time a Milestone Payment otherwise would have been due (as provided below) later becomes a Royalty Product upon issuance of a Royalty Patent, CPI will retroactively make the applicable Milestone Payment(s) to SVI (provided it has not already made such payment(s)) within forty-five (45) days of final determination that such New Lead is a Royalty Product, pursuant to Section 3 above.
Milestones Payments. Following the Second Restated Effective Date, Amicus will make milestone payments to GSK with respect to each Product in the Expanded Major Market Countries as set forth below. Amicus will pay to GSK the milestone payments set out below following the first achievement by Amicus, its Affiliate or Sublicensee of each of the corresponding milestone events that are achieved after the Second Restated Effective Date, such milestone payment to be made by Amicus to GSK no later than sixty (60) days following the receipt of an invoice from GSK therefor. Amicus shall notify GSK in writing promptly, but in no event later than ten (10) calendar days after the first achievement of each of the following milestone events, and no invoice for payment of a milestone shall be sent by GSK to Amicus as provided herein prior to GSK’s reasonable determination that the corresponding milestone event has been achieved. Each of the following milestone payments shall be payable only once with respect to the first Product (other than a Co-Formulation Product) to achieve such milestone event, regardless of the number of times such Product or any other Product achieves the milestone event, and no milestones shall be paid or payable by Amicus for milestone events that are not achieved after the Second Restated Effective Date. ******.
Milestones Payments. For the purpose of milestone payments, ADCT shall notify ADAGENE of the occurrence of any relevant milestone and shall pay ADAGENE within thirty (30) days of the milestone occurrence.
Milestones Payments. As additional consideration for the grant of rights under this Agreement, and on the terms and subject to the conditions set forth herein, in the event that the following milestone events (each a “Milestone Event” and collectively, the “Milestone Events”) are achieved by OV, its Affiliates, or permitted sublicensees following the expiration of the R-Pharm Option Term (where R-Pharm has not entered into a Reacquistion Agreement), then OV shall notify R-Pharm thereof in writing within five (5) Business Days (and R-Pharm shall promptly issue an invoice for the applicable Milestone Payment), and OV shall pay to R-Pharm the corresponding milestone payment associated with the applicable Milestone Event as set forth below (each a “Milestone Payment” and collectively the “Milestone Payments”) within thirty (30) days of receipt of an invoice issued by R-Pharm in respect of such Milestone Payment.
Milestones Payments. Company shall pay to Public Body the corresponding amounts to each milestone upon first occurrence of each of the following milestones as specified below. Company shall inform Public Body in writing of the first occurrence of each of the milestones. Each Milestone Payment shall be payable only once. Milestone Milestone Payment Acceptance of the patent in the SPTO, European Patents Office (EPO) and in the USTPO … Euros (€ …) per granted patent Acceptance for filing by either the FDA or the EMEA of the first complete BLA submission … Euros ( € …) per acceptance Orphan drug status granted by either the FDA or the EMEA … Euros (€ …) per status granted by each agency Receipt of Regulatory Approvals necessary to Commercialize the first Product in a Member State of the European Union (as of the Effective Date) … Euros (€ …) No payments for the following receipt of Regulatory Approvals in any Member State of the European Union Receipt of Regulatory Approvals necessary to Commercialize the first Product in the United States of America … Euros (€ …) First commercial sale in the Territory … Euros (€ …) Royalties. Company shall pay Public Body royalties payable on Net Sales on a calendar year started on the Effective Date and country by country basis. Applicable royalty rates shall be estimated on a consolidated basis for any given royalty payment, by application of (Option a; only a percentaje) a XX percent (XX % figures). (Opción b; payment in instalments) the corresponding percentage as set forth below. Percentage Annual Net Sales One point five percent (1,5%) Below two hundred and fifty thousand Euros (€ 250,000) Two percent (2,0%) Between two hundred and fifty thousand Euros (€ 250,000) and five hundred thousand Euros (€ 500,000) Three percent (3,0%) Above five hundred thousand Euros (€ 500,000) (To include an annual minimum plus applicable percentages on Net Sales, either by instalments or not) When the application of the royalty rates defined above results in an annual payment below XXXX Euros (€ XXXX en cifras), the above percentages will not be applicable and Company shall pay Public Body an annual payment of XXXX Euros (€ XXXX en cifras).
Milestones Payments. GSK will pay to Amicus the milestone payments set out below following the first achievement by GSK, its Affiliate or Sublicensee of each of the corresponding milestone events that are achieved after the effective date of such termination or the Co-Development Opt-Out Effective Date, as applicable, such milestone payment to be made by GSK no later than ****** following the receipt of an invoice from Amicus therefor. GSK shall notify Amicus in writing promptly, but in no event later than ****** after the first achievement of ****** - Material has been omitted and filed separately with the Commission. each of the following milestone events, and no invoice for payment of a milestone shall be sent by Amicus to GSK as provided herein prior to Amicus’s reasonable determination that the corresponding milestone event has been achieved. Each of the following milestone payments shall be payable only once with respect to the first Terminated Product (other than a Co-Formulation Product) to achieve such milestone event, regardless of the number of times such Terminated Product or any other Terminated Product achieves the milestone event, and no milestones shall be paid by GSK for milestone events that are not achieved after the effective date of such termination or the Co-Development Opt-Out Effective Date, as applicable. For clarity, no milestone payments shall be made with respect to a Terminated Product that is a Co-Formulation Product. Filing and Approval Milestone Event Milestone Payment 1. ****** $ ****** 2. ****** $ ****** 3. ****** $ ****** Sales Performance Milestones Milestone Payment 4. ****** $ ****** 5. ****** $ ****** For purposes of Milestone 4 and Milestone 5 in the table set forth above and the calculation of the royalty tiers in the table set forth in Sections 14.2.3(b)(i)(a) below, if the Terminated Product(s) is a Product(s) other than a Co-Formulation Product, the Net Sales of all such Terminated Products in the United States ******.
Milestones Payments. In addition, Servier would pay to Celladon, as and when due, the following payments with respect to the first and second Products (to the extent that such second Product is developed in indications within the Field other than those of the first Product) reaching the milestones below (collectively, the “Milestones”); provided, however, that if (i) development of a Product for a particular indication is abandoned after one or more of the Milestone payments has been made (a “Dropped Product”) and (ii) a Product containing a different Selected Compound is developed for the same indication as such Dropped Product (a “Replacement Product”), then Servier shall be entitled to credit any and all Milestone payments previously made with respect to such Dropped Product toward Milestone payment obligations accruing with respect to the Replacement Product. IND Filing of the first Product: [...***...] Euros First dosing of the first Product (or matched placebo or comparator drug) in the first Phase II: [...***...] Euros First dosing of the first Product (or matched placebo or comparator drug) in the first Phase III: [...***...] Euros First dosing of the second Product (or matched placebo or comparator drug) in the first Phase III: [...***...] Euros Acceptance of the filing of a first Marketing Authorization Application for the first Product by the EMA: [...***...] Euros Acceptance of the filing of a first Marketing Authorization Application for the second Product by the EMA: [...***...] Euros Acceptance of the filing of a first Marketing Authorization Application for the first Product in Japan: [...***...] Euros ***Confidential Treatment Requested Acceptance of the filing of a first Marketing Authorization Application for the second Product in Japan: [...***...] Euros First grant of a Marketing Authorization for the first Product by the European Commission following advice of the EMA: [...***...] Euros First grant of a Marketing Authorization for the second Product by the European Commission following advice of the EMA: [...***...] Euros First grant of a Marketing Authorization for the first Product in Japan: [...***...] Euros First grant of a Marketing Authorization for the second Product in Japan: [...***...] Euros
